Nektar Therapeutics (LTS:0UNL)
$ 1.0304 -0.0065 (-0.63%) Market Cap: 188.15 Mil Enterprise Value: 51.91 Mil PE Ratio: 0 PB Ratio: 3.86 GF Score: 53/100

Nektar Therapeutics at Goldman Sachs Healthcare Conference Transcript

Jun 14, 2023 / 08:20PM GMT
Release Date Price: $0.5713 (-2.01%)
Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

Welcome, everyone, to the afternoon start for the 44th Annual Goldman Sachs Healthcare Conference. My name is Chris Shibutani, member of the Biopharma Equity Research team. We are very pleased to have Nektar Therapeutics join us once again. On the dice with me are some veterans of the industry, of the company. Jonathan Zalevsky, also known as JZ, Chief Research and Development Officer; and Jen Ruddock, Chief Business Officer.

Thank you both for joining us.

Jonathan Zalevsky
Nektar Therapeutics - Senior VP & Chief Research and Development Officer

Thank you.

Chris Shibutani
Goldman Sachs Group, Inc., Research Division - Research Analyst

You guys have been really a part of so many aspects of the journey for the company. We're at an interesting intersection right now. A lot of changes going over the past 6 months, and probably changes that are not necessarily understood or recognized or appreciated as much. And I always

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot